<DOC>
	<DOCNO>NCT02550873</DOCNO>
	<brief_summary>This study Phase 2 , randomize , double-blind , placebo control , pilot study design evaluate efficacy safety PRM-151 administer Week 24 subject IPF .</brief_summary>
	<brief_title>A Trial Evaluate Efficacy PRM-151 Subjects With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description>PRM-151 anti-fibrotic immunomodulator develop treatment fibrotic disease .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Inclusion Criteria 1 . Is aged 4080 year . 2 . Has IPF satisfy American Thoracic Society/European Respiratory Society /Japanese Respiratory Society/Latin American Thoracic Association ( ATS/ERS/JRS/ALAT ) diagnostic criterion ( Raghu , Collard et al . 2011 ) . In absence surgical lung biopsy , HRCT must `` consistent `` usual interstitial pneumonia '' ( UIP ) define meet either criterion A , B , C , criteria A C , criterion B C : Definite honeycomb lung destruction basal peripheral predominance . Presence reticular abnormality AND traction bronchiectasis consistent fibrosis , basal peripheral predominance . Atypical feature absent , specifically nodules consolidation . Ground glass opacity , present , less extensive reticular opacity pattern . 3 . If pirfenidone nintedanib , subject must stable dose pirfenidone nintedanib least 3 month without increase FVC % predict two consecutive pulmonary function test ( PFTs ) , include screen PFTs . Subjects may pirfenidone nintedanib . 4 . If currently receive pirfenidone nintedanib , subject must pirfenidone nintedanib ≥ 4 week baseline . 5 . Has FVC ≥ 50 % ≤ 90 % predict . 6 . Has DLCO ≥ 25 % ≤ 90 % predict . 7 . Minimum distance 6Minute Walk Test ( 6MWT ) 150 meter . 8 . Has force expiratory volume 1 second ( FEV1 ) /FVC ratio &gt; 0.70 . 9 . Women child bear potential ( WCBP ) , define sexually mature woman surgically sterilize postmenopausal least 24 consecutive month ≤ 55 year 12 month &gt; 55 year , must negative serum pregnancy test within four week prior first dose study drug must agree use adequate method birth control throughout study . Adequate method contraception define protocol . 10 . Has life expectancy least 9 month 11 . According investigator 's best judgment , comply requirement protocol . 12 . Has provide write informed consent participate study . 1 . Has emphysema ≥ 50 % HRCT extent emphysema great extent fibrosis accord report result recent HRCT . 2 . Has history cigarette smoking within previous 3 month . 3 . Has receive investigational therapy IPF within 4 week baseline . 4 . Is receive systemic corticosteroid equivalent prednisone &gt; 10 mg/day equivalent within 2 week baseline . 5 . Received azathioprine , cyclophosphamide , cyclosporine A within 4 week baseline . 6 . Has history malignancy within previous 5 year , exception basal cell skin neoplasm . In addition , malignant diagnosis condition first occur prior 5 year must consider cured , inactive , current treatment . 7 . Has concurrent condition IPF , Investigator 's opinion , unstable and/or would impact likelihood survival study duration subject 's ability complete study design , may influence safety efficacy assessment include study . 8 . Has baseline rest oxygen saturation &lt; 89 % room air supplemental oxygen . 9 . Is unable refrain use following : Short act bronchodilator day within 12 hour pulmonary function , DLCO , 6 minute walk assessment . Long acting bronchodilator day within 24 hour assessment . 10 . Has know post bronchodilator ( short act beta agonist [ SABA ] albuterol salbutamol ) increase FEV1 &gt; 10 % FVC &gt; 7.5 % .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>